The French study found that children with MS were almost twice as likely to have received the vaccine called Engerix B three or more years before the disease's onset. Further studies will need to be done to determine whether the vaccine is a direct cause of the development of MS.

The study, which involved 349 children with MS and 2,941 children without the disease, is to be published in the Oct. 8 online issue of Neurology.